Workflow
市场关注度持续提升,港股医药板块早盘再度走强,恒生创新药ETF(159316)、港股通医药ETF(513200)标的指数创年内新高
Mei Ri Jing Ji Xin Wen·2025-06-05 02:54

Group 1 - The Hong Kong pharmaceutical sector has seen a significant rise, with companies like Zai Lab and SiHuan Pharmaceutical increasing by over 7% [1] - The Hang Seng Innovation Drug ETF (159316) and the Hong Kong Stock Connect Pharmaceutical ETF (513200) both tracked indices that rose over 1%, reaching new highs for the year [1] - In May 2025, Chinese innovative pharmaceutical companies showcased 71 original research results at the ASCO conference, highlighting their international leadership in innovation and research [1] Group 2 - Recent approvals for multiple innovative drugs in China cover various cutting-edge treatment areas, indicating a significant enhancement in the ability of domestic innovative drugs to transition from research to commercialization [1] - Some innovative products have achieved a positive feedback loop in R&D investment returns under the current domestic innovation payment system, with sales reaching new highs [1] - The Hang Seng Innovation Drug ETF (159316) is the first ETF tracking the Hang Seng Stock Connect Innovation Drug Index, focusing on companies involved in innovative drug research, development, and production [2]